Journal of Pharmaceutical Analysis, 2024, 101022, ISSN 2095-1779
This study developed four deep learning models to identify potential Alzheimer's disease treatments from traditional Chinese medicine, specifically the Kaixinsan formula. The models successfully predicted compounds that showed significant anti-Alzheimer's activities in various experimental validations.
Elsevier,
IBRO Neuroscience Reports, Volume 16, June 2024
This article summarizes current biomarkers, available treatments, and future therapeutic approaches for Alzheimer's disease, discussing drug targets like Amyloid β, Tau Protein, and various other mechanisms. Additionally, it highlights the historical use of Estradiol, outcomes of trials with antioxidants and omega-3 fatty acids, and ongoing clinical trials, providing a comprehensive overview of the evolving landscape in AD research and treatment.
Elsevier,
Molecular and Cellular Neuroscience, Volume 129, June 2024
Neurological disorders affect approximately one billion people worldwide, with significant disability and mortality impacts, and this review explores how Heparan sulfate proteoglycans (HSPGs) promote Tau fibril formation and tangles in Alzheimer's disease, and the potential role of tunnelling nanotubes (TNTs) in the intercellular transport of Tau and Amyloid β proteins, suggesting that HSPGs may influence TNT formation in neurodegenerative conditions.
Elsevier,
Neurochemistry International, Volume 176, June 2024
This study finds that impaired cellular immune dysfunction in AD patients was significantly correlated with abnormal MRS, and neuroimmune dysfunction may contribute to the pathogenesis of AD and alter the metabolism of neurotransmitters such as aspartic acid and MI in the brains of AD patients.
